Država: Irska
Jezik: angleščina
Source: HPRA (Health Products Regulatory Authority)
Enrofloxacin
Laboratorios Hipra S.A.
QJ01MA90
Enrofloxacin
100 milligram(s)/millilitre
Oral solution
POM: Prescription Only Medicine as defined in relevant national legislation
Chickens, Turkeys
enrofloxacin
Antibacterial
Authorised
2010-11-19
Health Products Regulatory Authority 19 July 2018 CRN000YRP Page 1 of 7 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT SPECTRON 100 mg/ml solution for use in drinking water for chickens and turkeys 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: ACTIVE SUBSTANCE: Enrofloxacin................................ 100 mg For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Solution for use in drinking water.Slightly yellowish clear solution. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Chickens and Turkeys. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Treatment of infections caused by the following bacteria susceptible to enrofloxacin: CHICKENS _Mycoplasma gallisepticum, _ _Mycoplasma synoviae, _ _Avibacterium paragallinarum, _ _Pasteurella multocida._ TURKEYS _Mycoplasma gallisepticum, _ _Mycoplasma synoviae, _ _Pasteurella multocida._ Health Products Regulatory Authority 19 July 2018 CRN000YRP Page 2 of 7 4.3 CONTRAINDICATIONS Do not use for prophylaxis. Do not use when resistance/ cross-resistance to (fluoro)quinolones is known to occur in the flock intended for treatment. Do not use in case of known hypersensitivity to the active substance, to other (fluoro)quinolones, or to any of the excipients. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Treatment of _Mycoplasma_ spp. infections may not eradicate the organism. 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS Before use, header tanks should be emptied, thoroughly cleaned and then filled with a known volume of clean water before adding the required amount of the veterinary medicinal product. The resulting mixture should be stirred. Official and local antimicrobial policies should be taken into account when the product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials. Whenever possible, fluoroquinolones should only be used based on susceptibi Preberite celoten dokument